Format

Send to

Choose Destination
Nanomedicine (Lond). 2016 Feb;11(3):307-20. doi: 10.2217/nnm.15.200. Epub 2016 Jan 20.

Cancer stem cells and personalized cancer nanomedicine.

Author information

1
Drug Delivery & Targeting Group; CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
2
Networking Research Center on Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN), Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
3
iMed.ULisboa, Research Institute for Medicines. Faculdade de Farmácia da Universidade de Lisboa, Av Prof Gama Pinto, 1649-003 Lisboa, Portugal.
4
Functional Validation & Preclinical Studies (FVPR); CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
5
Inmunobiology Group; CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
6
Molecular Oncology Group; CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca (VHIR), Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.

Abstract

Despite the progress in cancer treatment over the past years advanced cancer is still an incurable disease. Special attention is pointed toward cancer stem cell (CSC)-targeted therapies, because this minor cell population is responsible for the treatment resistance, metastatic growth and tumor recurrence. The recently described CSC dynamic phenotype and interconversion model of cancer growth hamper even more the possible success of current cancer treatments in advanced cancer stages. Accordingly, CSCs can be generated through dedifferentiation processes from non-CSCs, in particular, when CSC populations are depleted after treatment. In this context, the use of targeted CSC nanomedicines should be considered as a promising tool to increase CSC sensitivity and efficacy of specific anti-CSC therapies.

KEYWORDS:

active targeting; bioluminescent CSC models; cancer stem cells; metastasis; nanomedicine; tumor recurrence

PMID:
26785724
DOI:
10.2217/nnm.15.200
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center